Acurx Pharmaceuticals, Inc. (ACXP): Total Assets
$7.69M
As of 2025-12-31
$10.98M
As of 2026-06-30
-6.4%
3-year compound annual growth
+19.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.69M | +99.3% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $3.86M | -50.0% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $7.71M | -17.8% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $9.38M | -29.3% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $13.25M | +311.1% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $3.22M | n/a | 2022-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $7.69M | +99.3% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $7.61M | +2.6% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $7.60M | -1.4% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $7.58M | -43.5% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $7.81M | +142.0% |
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $7.86M | +122.5% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $7.45M | +33.1% |
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $7.34M | +454.5% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $8.11M | n/a |
Compare ACXP, SILO, RKTO, ONCY side by side · Screen every company in Pharmaceutical Preparations ↗